Artiva Biotherapeutics, Inc. ARTV · Stock Open Artiva Biotherapeutics, Inc. in new tab
Analyst price targets
Recent rating changes, newest first
Artiva Biotherapeutics, Inc. Analysis (ARTV)
Is Artiva Biotherapeutics, Inc. a good investment? Artiva Biotherapeutics, Inc. (ARTV) is currently trading at 4.22 USD. Market analysts have a consensus price target of 20.75 USD. This suggests a potential upside from current levels.
Earnings Schedule: Artiva Biotherapeutics, Inc. is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is -1.98.
Investor FAQ
Does Artiva Biotherapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Artiva Biotherapeutics, Inc.?
Artiva Biotherapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of -3.23.
Company Profile
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
Community Discussion